Table 1 Characteristics of included adult studies.
Country | Trauma sample | Pharmacotherapy | Timing after trauma | Comparator | n | PTSD/ASD outcome | Follow up | |
|---|---|---|---|---|---|---|---|---|
Delahanty et al.* | USA | Injury | Hydrocortisone | <12 h | Placebo | 43 | PTSD Severity (CAPS) | 1, 3 months |
Denke et al.* | Germany | Septic Shock | Hydrocortisone | <6 h | Placebo | 18 | PTSD Incidence (PTSS-10) | 12 months |
Schelling et al.* | Germany | Septic Shock | Hydrocortisone | <6 h | Placebo | 20 | PTSD Incidence & Severity (SCID-IV & PTSS-10) | 31 months |
Schelling et al. | Germany | Zohar et al.* | Hydrocortisone | <6 h | Standard therapy | 48 | PTSD Severity (PTSS-10) | 6 months |
Weis et al.* | Germany | Cardiac Surgery | Hydrocortisone | <6 h | Placebo | 28 | PTSD Incidence (PTSS-10) | 6 months |
Zohar et al.* | Israel | Injury | Hydrocortisone | <6 h | Placebo | 17 | PTSD Incidence (CAPS) | 3 months |
Kok et al.* | Netherlands | Cardiac Surgery | Dexamethasone | <6 h | Placebo | 2458 | PTSD Incidence (PTSS-10) | 18–48 months |
Hoge et al.* | USA | Injury | Propranolol | 4–12 h | Placebo | 41 | PTSD Incidence & Severity (CAPS) | 1, 3 months |
Pitman et al.* | USA | Injury | Propranolol | <6 h | Placebo | 24 | PTSD Incidence & Severity (CAPS) | 1, 3 months |
Stein et al.* | USA | Injury | Propranolol | <48 h | Placebo | 38 | ASD Severity & PTSD Incidence (ASDS & PCL-C) | 1, 4, 8 months |
Shalev et al.* | Israel | Injury | Escitalopram | 19.8 days | Placebo | 36 | PTSD Incidence & Severity (CAPS) | 5, 9 months |
Suliman et al.* | South Africa | Injury | Escitalopram | <28 days | Placebo | 29 | PTSD Incidence (CAPS) | 0.5, 6, 14 months |
Zohar et al. | Israel/South Africa | Injury | Escitalopram | <30 days | Placebo | 198 | PTSD Severity (CAPS) | 14 months |
Van Zuiden et al.* | Netherlands | Injury | Oxytocin | <12 days | Placebo | 107 | PTSD Incidence & Severity (CAPS) | 1.5, 3, 6 months |
Matsuoka et al.* | Japan | Injury | Fish oil (1470 mg DHA/147 mg EPA) | 10 days | Placebo | 110 | PTSD Incidence & Severity (Clinical Diagnosis & CAPS) | 3 months |
Nishi et al. | Japan | Disaster Relief | Fish oil (224 mg DHA/22.4 mg EPA) | Not specified | Psychoeducation | 172 | PTSD Incidence (IES-R) | 12.6 weeks |